Effect of Calcium Channel Antagonists and Sex on
Bone Metabolism in Aged Brown Norway Rats

A Thesis
Presented to
the Faculty of the College of Science & Technology
Morehead State University

In Partial Fulfillment
of the Requirements for the Degree
Master of Science
f

by
Brent Kidd
April 2007

ms (,k THESES
57'J.'-f
K '--i !oe

Accepted by the faculty of the College of Science and Technology,
Morehead State University, in partial fulfillment of the requirements for the
Master of Science Degree.

Master's Committee:

Date

Effect of Calcium Channel Antagonists and Sex on
Bone Metabolism in Aged Brown Norway Rats

Brent Kidd, M. S.
Morehead State University, 2007

Director of

Thesi✓.--" t,.-2--- ,:::. ~ [

Calcium channels are a potential point of regulation for skeletal remodeling and
calcium channel antagonists are utilized therapeutically and experimentally to
decrease the influx of calcium into cells by blocking voltage-regulated L-type
calcium channels. Previous experimental evidence has suggested that calcium
channel antagonists decrease osteoblastic activity, thus decreasing the activity of the
bone forming cells in aged animals at a time when bone formation is already
exceeded by bone resorption, exacerbating the situation. Therefore, the established
principle that bone formation decreases following the attainment of peak bone mass,
establishes the need for a more comprehensive understanding of the action calcium
channel antagonists have on bone turnover. The experimental design in this research
used six month old male and female Brown Norway Rats in order to compare the
effects of sex and calcium channel antagonists on blood pressure and bone turnover
from both the bone fluid and calcified compartments. In order to evaluate the
positive or negative impact of various calcium channel antagonists on bone loss, bone

resorption parameters were compared between normal males and females, to those
receiving the calcium channel antagonists diltiazem, nifedipine, or verapamil. The
model utilized to study bone turnover was the pharmacokinetic loss of the tracer 3 Htetracycline, a compound deposited in the active mineralization front and freely
released in urine throughout the experimental period. The turnover of 3 H-tetracycline
was also studied in the bone fluid compartment by leeching the label from designated
bones of the axial and appendicular skeleton oflabeled rats. The results from these
two types of experimentation clearly suggest the presence of a rapidly exchangeable
pool (bone fluid compartment) and a stable pool (calcified compartment). The impact
of the calcium channel antagonists on pool turnover in each of these highly regulated
calcium pools is significant in both male and female treatment groups.
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INTRODUCTION

This project was designed to enhance the understanding of the action elicited by
calcium channel antagonists on bone resorption, through the utilization of organismal
techniques. The holistic protocols and the subsequent analysis will focus on the
effects that calcium channel antagonists have on skeletal physiology in both male and
female aged Brown Norway Rats. The proposed study will examine the hypothesis
that bone resorption is regulated by the influx of Ca* ions and since calcium channel
antagonists are known to block the transport of calcium in cardiovascular tissue we
would expect these drugs to have a similar impact on calcium movement in skeletal
tissue. The specific objectives outlined in the experimental design and analysis were
twofold. First, to determine what aspects of bone resorption are affected by calcium
channel antagonists in both male and female aged rats through the use of the 3H3

tetracycline rat model, and second to determine the feasibility of extracting Htetracycline from the bone fluid compartment, and if these values correlate with data
obtained for the bone fluid compartment during the metabolic studies.

Role of Estrogen in the Regulation of Bone Resorption

Osteoporosis has been viewed as a primary disease among women for over 100
years (Brun, 1882). Albright, et.al., (1940 and 1947) first linked osteoporosis to
estrogen in a series of papers indicating the prevalence of negative calcium balance
among osteoporotic women and demonstrated its reversal in osteoporotic

postmenopausal women through the use of estrogen therapy. A number of
subsequent studies have indicated that women show a gradual reduction in bone mass
from about the age of 20 (Recker et al, 1992 and Riggs et al, 1985 and 1982,) with
accelerated losses at menopause (Jasani et al, 1965, Lindsay et al, 1992, and Nordin et
al, 1966). Postmenopausal changes in the skeleton include both bone loss and
changes in its architecture. A major characteristic of bone loss following loss of
ovarian function is the widespread loss of intertrabecular connections, which may
significantly decrease mechanical strength (Dempster et al, 1986). Surprisingly, even
the gross nature of the changes in bone cell activity that lead to these alterations in
postmenopausal bone is not certain. There clearly is increased activation of
resorption with new remodeling sites leading to an increased amount of surface
remodeled (Parafit, 1984). However, it is also suggested that the qualitative nature of
osteoclast resorption (deeper resorption cavities) (Parafit et al, 1983 and 1984), the
uncoupling of resorption/formation (Ivey et al, 1981) or simply decreased osteoblast
formation of bone (Lips et al, 1978) may be principal causes of bone loss in estrogen
deficiency.
The action of estrogen on skeletal physiology has been known for quite some time
but the cellular basis for its action is uncertain. Because there is increased
frequency of activation of new remodeling sites after ovariectomy and menopause, it
has been proposed that estrogen may act to prevent contraction of osteoblasts lining
the bone surfaces (Rodan and Martin, 1981) leading to exposed bone surface and
initiation of resorption by osteoclasts. Research by Earnst and Rodan (1989) and
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Gray et al (1998) on estrogen-mediated proliferation of osteoblasts in culture
suggested that the steroid acted directly on this bone cell type to ultimately inhibit
osteoclasts. However, it should be noted that estrogens have only been shown to be
effective in decreasing bone resorption at high doses under in vitro conditions (Jilka
et al, 1992, Manolagsas and Jilka, 1992, and Pacifici et al, 1991). Others have
suggested that estrogen influences bone remodeling indirectly through the induction
of other mediator compounds in peripheral tissues (Pacifici et al, 1991) or in bone
cells (Jilka et al, 1992, and Manolagsas and Jilka, 1992). In particularly elegant
work, Poli, et.al., (1994) have shown that interleukin-6 deficient transgenic mice were
protected from bone loss by estrogen deficiency, supporting the concept that estrogen
could act to suppress active mediators of bone resorption. This latter study
underscores the potential complexity of the interactions that may exist in the pathway
employed by estrogen regulation of bone mineral metabolism and may explain the
confusion of information derived from bone and cell culture studies.

Role of Cellular Calcium in the Regulation of Bone Resorption
Bone metabolism is invariably correlated with calcium transport. Therefore,
calcium channels are a potential point of regulation for skeletal remodeling. In an
attempt to address the role of calcium transport, calcium channel antagonists can be
employed to probe the role of calcium channels in this process. These antagonists are
commonly utilized therapeutically for their blood pressure lowering properties and
experimentally to decrease the influx of calcium into cells by blocking voltage-
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regulated calcium channels. Calcium channel antagonists present heterogeneity of
structure and variable pharmacologic function, these three principle classes of
calcium channel antagonists associate with different regions of the L-type calcium
channel (Epstein, 2002). A number of studies have also indicated that representatives
from each of the major classes of calcium channel blockers (verapamil, nifedipine,
and diltiazem) may also influence skeletal bone metabolism. For example, it has
been demonstrated that calcium channel blockage decreased both parathyroid
hormone (Hermann- Erlee et al, 1977) and 1,25-hydroxyvitamin D3-induced (Lerner
and Gustafson, 1982 and Ly et al, 1985) bone resorption in vitro. Verapamil has been
shown to increase bone loss in uremic rats (Chagnac et al, 1989) and there is
convincing evidence that calcium channel blockers have a direct inhibitory effect on
osteoblast function (Kim et al, 1991). More recently, it has been shown that
epidermal growth factor-induced osteoblastic cell proliferation is caused by an
increase in intracellular calcium, primarily due to extracellular calcium influx (Loza
et al, 1995). These findings strongly suggest that a number of regulatory molecules
that increase bone resorption may utilize the elevation of intracellular calcium as one
element in the transduction pathway. However, it has been shown that 17~-estradiol
inhibited calcium influx and intracellular release of calcium by thrombaxane A2 in
coronary artery smooth (Han et al, 1995) and reduced systolic intracellular calcium
concentration through the inhibition of calcium influx in cardiac myocytes (Jiang et
al, 1992). Hence, it appears that estrogen could act directly or indirectly (through
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secondary mediators) to attenuate resorption activity through the inhibition of calcium
influx in opposition to the action of other regulatory agents tending to increase bone
resorption.
History of the 3H-Tetracycline Rat Model
The laboratory rat exhibits the same physiological mechanisms for bone growth
modeling and remodeling as seen in humans (Frost and Jee, 1992). Both trabecular
and cortical bone masses increase during growth while bone remodeling in the rat
results in the removal of bone from the endocortical and trabecular envelopes
(Kimmel and Jee, 1980 and Li et al, 1991). Unlike humans, rats possess few primary
Haversian systems and few, or no, secondary Haversian systems. However, this may
be viewed as a positive feature of the model because of the relative lack of
remodeling in the intracortical envelope accents the resorptive losses from the
endocortical and trabecular envelopes, which are the types of remodeling, observed in
various human bone diseases. Relevant to the present proposal, the ovariectomized
rat provides a recognized model of estrogen deficiency osteoporosis.
In vitro systems cannot adequately represent the multiple interacting hormonal

and mechanical influences on bone metabolism therefore, an in vivo model utilizing
whole animals is more ideal. In this regard, the 3H-tetracycline rat model enables the
quantitative measurement of bone resorption with time. 3H-tetracycline possesses the
major characteristics of an excellent label for use in the evaluation of bone resorption.
This compound avidly binds to bone at the mineralization front and becomes widely
distributed throughout the skeleton (Bloomquist and Hanngren, 1968 and Kohn,
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1961). The loss of 3H-tetracycline from bone is irreversible such that the compound
is unavailable for reutilization (Frost, 1965). The release of tetracycline from bone
has been shown to reflect both the destruction of the bone matrix and the loss of
inorganic material and is, thus, physiologically relevant and a direct indicator of bone
resorption (Klein et al, 1983). 3H-tetracycline is extremely stable both in vivo (Kelley
and Buyske, 1969) and in vitro (Chen and Klein, 1978) and the tissue concentration is
directly related to calcium content (Bloomquist and Hanngren, 1968). Renal
excretion of the compound is very efficient with a circulatory half-life of2.8 hours
(Raghuram et al, 1982) and complete elimination from soft tissues within 24 hours in
the rat (Bloomquist and Hanngren, 1968). Limitations on the use of tetracycline as a
marker for bone resorption include its restriction to animals with normal renal
function and an inability to accurately monitor resorption during intervals of rapid
change. In summary, the combination of 3H-tetracycline affinity for bone, its
physiologically relevant release from bone, its rapid clearance from circulation and
soft tissue, and only minor restrictions on its use highly recommends this compound
for the noninvasive assessment of bone resorption.
Klein and associates (Klein et al, 1983 and Li et al, 1989) pioneered the use of the
3

H-tetracycline/rat model and provided ground-breaking work in the study of age

related changes in bone resorption. They concluded that the loss of 3H-tetracycline in
urine was described by a monoexponential curve indicating loss from a single
compartment. However, more recent studies conducted by DeMoss and colleagues
have resulted in a number of modifications to the various protocols used in this
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method which greatly improves its utility in the quantitative evaluation of skeletal
resorption in vivo (DeMoss and Wright, 1997 and 1998, Geng et al, 2000, Wright et
al, 2000, and Wright and DeMoss, 2000). However, the whole animal model does
not allow the elucidation of the mechanisms involved in bone resorption at the
cellular or molecular level, as an in vitro model or analysis of gene activity could.
Therefore, holistic and molecular models will be necessary to elucidate the
mechanisms of regulated bone metabolism.

Refinement of 3H-tetracycline Model
DeMoss et al refined the 3H-tetracycline rat model and improved the quantitative
assessment of skeletal resorption (DeMoss and Wright, 1997 and 1998, Geng et al,
2000, Wright et al, 2000, and Wright and DeMoss, 2000). Utilizing Table Curve 2D
Automated Curve Fitting Software in analyses to determine best fit equations
(DeMoss and Wright, 1998), established that the urinary loss of 3H-tetracycline from
day 2 through day 35 is best described by a double exponential equation indicating a
two component model comprised of two distinct bone calcium pools. This analysis
further provided the determination of: y-intercept, the uncomplicated rate oflabel loss
at time zero with the bone pool fully labeled; t, the time constant for depletion of the
pool and; (Cy-intercept (t x 5))/2), the size of the labeled pool.
3

As one major modification of the method previously employed with the Htetracycline rat model, the labeling protocol was shortened so that isotope injections
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were administered for only two weeks prior to urinary loss measurements. It may be
argued that animals must be injected from 1 to 3 weeks of age through the entire
interval prior to the start of measurements to ensure a complete labeling of deep bone
during intervals ofrapid skeletal growth (Klein et al, 1983 and Li et al, 1989). Thus,
DeMoss and Wright (1998) demonstrated that the 2-week labeling interval was
adequate to label areas of active bone resorption in mature animals . Moreover, the 2week labeling procedure was found to result in urinary loss curves that were similar
to those that were labeled from birth to 8 weeks of age (DeMoss and Wright, 1998).
Although intuitively one may wish for a complete labeling of bone throughout, the
real objective of the labeling procedure is to label those areas of active bone
metabolism. The rat, however, does not undergo intracortical remodeling (few or no
secondary Haversian Systems) so that bone turnover is confined to surface areas.
DeMoss and colleagues (DeMoss and Wright, 1997 and 1998, Geng et al, 2000,
Wright et al, 2000, and Wright and DeMoss, 2000) data suggests that, because deep
bone resorption is quiescent, it is not essential to label deep bone and the 2-week
protocol employed is adequate to thoroughly label the relevant areas of bone
turnover. Moreover, the analysis employed bases comparisons between groups not
only on the rate oflabel efflux from the skeleton but also on the pool size and the rate
of depletion of the labeled pool. It can, therefore, be argued that labeling of the
available bone surface sites for tetracycline binding provides an accurate measure of
relative resorption activities between groups.
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In the past, tetracycline release from the skeleton was expressed on the basis of
body weight or as total DPM excreted. In order to place results on an appropriate
basis DeMoss and Wright (1997) sacrificed 4 to 24-week old male and female rats
from three strains (Sprague Dawley, Wistar Kyoto, Spontaneously Hypertensive
Rats) specifically for the determination of dry skeletal weight and total dry skeletal
calcium content. This work clearly demonstrated the relationship between body
weight and dry skeletal mass is linear within groups but that significant differences
exist between strain and sexes. Most interestingly, it was found that the ratio of
skeletal mass to body weight in mature females was 30% to 40% greater than in
males. Because this relative increase in skeletal development cannot be due to
increased demand for mechanical support in the smaller female, these results have a
number of interesting implications regarding the regulation of bone formation and
skeletal maintenance in mature, ovary-intact females. These findings enabled the
development of regression equations for the calculation of whole skeletal mass
following the determination of body weight (DeMoss and Wright, 1997). The
relationship between skeletal mass and calcium content indicate that the degree of
calcification per gram of dry skeletal mass or total skeletal calcium would be
appropriate parameters for the expression of 3H-tetracycline loss in urine (DeMoss
and Wright, 1997). However, body weight is an inappropriate parameter due to
significant gender and strain related differences in the ratio of skeletal mass to body
weight. It may be argued that resorption data cannot be expressed in dpm/skeletal
weight because of growth, which will show a loss in activity due to dilution in older,
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larger animals (Li et al., 1989). On the other hand, if the same level oflabel loss is
observed in an animal half the size of another, one may suspect that the relative rate
of bone turnover in the smaller animal is high compared to that of the large animal.
In light of DeMoss and Wrights (1998) findings that the ratio of skeletal weight is
significantly different between sexes and among rat strains, it is necessary to express
resorption data on the basis of skeletal weight for quantitative comparisons between
groups. In addition, regression analysis has been utilized to further define the
relationships among body weight, whole skeleton bone resorption, and the
development of skeletal mass. DeMoss' results indicated that skeletal development
(%bodyweight) of slowly growing, 24 week-old rats consisted of two major
components, one directly and one inversely related to body weight. It was further
noted that the skeletal resorption rate was inversely correlated to body weight and
directly related to skeletal development, suggesting that whole skeleton bone
resorption and formation were highly correlated in the slowly growing animal. A
third small component of skeletal development identified in the analysis of data from
24 week-old animals, showed no direct relationship to either body weight or
resorptive activity. The model presented enables the separation of skeletal mass into
major components, which may represent mechanically and metabolically driven bone
formation (Wright et al, 2000).
In order to further characterize the two bone calcium pools reflected in the loss of
3

H-tetracycline in urine, a study conducted by DeMoss (unpublished) to monitor the

loss oflabel from a selection of 12 individual bones removed at selected intervals
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from rats injected with the isotope. The amount oflabel remaining in the bones was
then determined by extracting the compound with 0.5N HCL for liquid scintillation
counting. The best-fit analysis of these data indicated that the label loss was
described by a single exponential with an offset indicating the presence of a
resorbable and a nonresorbable pool. Because two resorbable compartments were
identified from 3H-tetracycline urinary loss curves while only one was obtained from
the 3H-tetracycline content of individual's bones, it was of interest to determine if
significant label loss occurred during the processing of individual bones. In
subsequent experiments, it was found that significant loss oflabel did occur during a
water wash used prior to the HCL extraction. It was then calculated that 23.2% of the
total label in individual's bones was located in a water-soluble pool, 40.3% in a
resorbable but water-insoluble pool, and that the remaining 36.5% was not resorbed.
Assuming that 36.5% of the skeletal 3H-tetracycline was nonresorbable, it was further
calculated that the rapidly depleted and the slowly depleted components of the urinary
label loss curves represented 25.3 and 38.2% of total label, respectively. DeMoss and
colleagues concluded that the rapidly depleted pool of urinary 3H-tertacycline loss
represents calcium loss from a water soluble, amorphous, bone associated calcium
compartment (bone fluid); whereas, the slowly depleted component of urinary loss
reflects the active resorption of calcified bone (Wright and DeMoss, 2000 and Wright
et al., 2000).
In previous use of the model, it has been the standard procedure to eliminate the
first 7 days of urine tetracycline losses from analysis (Li et al., 1989) because of the
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potential for contamination of bone label losses with that from soft tissues. However,
there are at least 4 lines of evidence indicating that DeMoss and colleagues
contention of tetracycline loss from a rapidly depleted, water-soluble bone
compartment has merit and is not related to soft tissue losses of the compound. First,
direct measurements of tissue tetracycline-associated fluorescence and radioactivity
indicated that even soft tissues of the sub lingual gland and parathyroid gland which
accumulate tetracycline to a remarkable degree, are devoid of the compound by 24
hours (Bloomquist and Hanngren, 1968). Secondly, it was determined that nearly
25% of the tetracycline label of individual bones is removed by simply soaking whole
bones in water for as little as 6 hours (DeMoss, unpublished). Third, various
estimates indicate that up to 90% of the label recovered in urine occurs in the frrst 24
hours (Li et al., 1989). This level of isotope loss clearly does not fit the doubleexponential regression equation for what is referred to as the fast component of
urinary loss (bone fluid compartment). Finally, the data indicates that the rate oflabel
loss from the fast compartment is increased by decreasing the calcium content within
the diet (Geng et al., 2000). There is little reason to believe that this experimental
manipulation would affect soft tissues depletion; whereas, the resulting challenge to
calcium homeostasis would be expected to increase the loss oflabel from an
amorphous calcium component of bone.

12

Bone Fluid Compartments Role in Ca++ Homeostasis

The skeleton serves as a storehouse for Ca++ and Pol-. Approximately 99% of
the bodies' total calcium is stored in bone and is exchanged between bone mineral, a
labile calcium pool, and the extracellular fluid daily as bone undergoes remodeling
(Goodman, 1996 and Sherwood, 2007). This Ca++ is essential in many of the bodies'
mechanisms and can be found in two separate compartments in bone, the labile pool
which consists of bone fluid (amorphous) and the stable pool which is composed of
calcified bone (Sherwood, 2007). DeMoss and colleagues have published several
papers utilizing a modified analysis of the 3 H-tetracycline rat model for bone
resorption that reinforces the existence of the two distinct bone calcium pools, one of
which is a water-soluble pool (DeMoss and Wright, 1997 and 1998, Geng et al, 2000,
Wright et al, 2000, and Wright and DeMoss, 2000). This water-soluble pool
composed of bone fluid can act as an immediate source of Ca++ to help maintain a
homeostatically regulated plasma concentration of Ca++_ This balance is maintained
mainly by the hormone parathyroid hormone (PTH) which can facilitate both
immediate and chronic effects on Ca++ homeostasis. Morphological studies suggest
that this system responds within several minutes of exposure to PTH (Davis et al,
1975, Harrison and Fraser, 1960, and Matthews and Talmage, 1981), thus providing
the body with an extracellular fluid buffering mechanism of rapid proportion (Aarden
et al, 1994, Matthews et al, 1980, and Menton et al, 1984). Therefore, the bone fluid
compartment plays a critical role in reestablishing the plasma Ca++ concentration
during periods ofhypocalcemia. However, when the body undergoes a chronic
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period ofhypocalcemia, PTH will act on bone stimulating the bone resorption process
that leads to the release of Ca++ from the bone itself. This system helps explain how
the destruction of calcified bone is involved in the maintenance of the plasma Ca++
concentration.

Bone Degradation Markers
The organic matrix of bone consists of approximately 90% type I collagen (Seibel
and Woitge, 1999). Trifunctional pyridinium crosslinks - pyridinoline (Pyd) or
deoxypyridinoline (Dpd) - form between hydroxylysine or lysine residues at the Cand N-telopeptide ends of one collagen molecule and the helical portion of a
neighboring molecule during collagen maturation (Seibel et al, 1992 and 1999). This
crosslinking provides structural rigidity to the collagen fibril. Osteoclastic
degradation of bone collagen releases the crosslinks into circulation, and they are
eventually excreted in urine. Though the crosslinks are present in a number of
tissues, the molar ratio of Pyd and Dpd in urine is very similar to that in bone,
indicating that urinary concentrations of both are derived mainly from bone. Dpd in
particular, with a more limited tissue distribution than Pyd, is derived almost
exclusively from bone (Delmas, 1995, Eastell et al, 1997, James et al 1996, Robins,
1995, Roux et al, 1995, and Seibel et al, 1992 and 1999). As products of collagen
maturation, they cannot be reused in new collagen synthesis, nor are they further
metabolized (Delmas, 1995, Seibel and Woitge, 1999, and Robins, 1995). Of the
total pool of urinary Dpd/Pyd, approximately 40-45% is free and the remainder is
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bound to peptides (Seibel et al, 1992 and Robins, 1995). The total excretion of
Dpd/Pyd measured by high performance liquid chromatography (HPLC) is correlated
with histomorphometric resorption indices of iliac crest biopsies, and with
radioisotope kinetic estimates of whole body bone resorption (Eastell et al, 1997 and
Roux et al, 1995). Free Dpd/Pyd can be measured both by HPLC and by a highly
specific enzyme immunoassay (Robins et al, 1994). Free Dpd levels measured by
immunoassay are highly correlated with free or total Dpd/Pyd measured by HPLC
(Robins et al, 1994). Increased urinary levels ofDpd are observed among
postmenopausal women compared to premenopausal women and are associated with
rapid bone loss and an increased risk of hip fracture (Gamero et al, 1996, Hesley et al,
1998, Ross and Knowlton, 1998, and V anDaele et al, 1996). Increased Dpd excretion
is seen in a number of conditions characterized by excessive bone resorption
including osteoporosis, Paget' s disease, hyperparathyroidism, thyrotoxicosis,
malignant hypercalcemia, and metastatic cancer (Delmas, 1995, Seibel et al, 1992,
and Robins et al, 1994). Dpd/Pyd levels decrease rapidly following antiresorptive
therapy in a dose-dependent manner (Delmas, 1995, Gamero et al, 1994, and Hesley
et al, 1998). These short-term changes are inversely correlated with long-term
changes in bone mineral density (Gamero et al, 1994 and Hesley et al, 1998).
Elevated pyridinium crosslink levels, particularly of Pyd, are also seen in rheumatoid
arthritis and osteoarthritis and correlate with disease activity (Gerrits et al, 1995,
Gough et al, 1994, Seibel et al, 1989, and Thompson et al 1992). The organic matrix
of bone contains approximately 90% type I collagen, a helical, heterotrimeric
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molecule comprising two al chains and one u2 chain (Seibel and Woitge, 1999). A
number of markers of collagen degradation have been described, including modified
amino acids, peptides, and intermolecular crosslinks (Seibel and Woitge, 1999). The
pyridinium crosslinks and related amino- and carboxyterminal telopeptides of type I
collagen have been well validated as markers of bone resorption (Miller et al, 1999
and Seibel and Woitge, 1999). These markers reflect degradation of the nonhelical
end region of collagen and that modified amino acids are distributed throughout the
molecule. No marker has enabled assessment of degradation of the helical region that
makes up the bulk of type I collagen. Ju et al (1997) identified a 14 amino acid type I
collagen helical region peptide that was isolated from the urine of an individual with
Paget's disease and developed a specific competitive enzyme immunoassay to
measure it. Increased urinary levels of helical peptide ul(I) 620-633 were observed
in postmenopausal women with osteoporosis and in individuals with Paget' s disease,
conditions characterized by elevated bone collagen degradation (Ju et al, 1997).
Helical peptide levels decreased following therapy with estrogen or bisphosphonate
reflecting the antiresorptive effect of these agents (Ju et al, 1997 and Ju et al, 1998).

Clinical Significance
Drugs classified as calcium channel antagonists have been in use in clinical
medicine since the 1960's and are among the most frequently prescribed drugs for the
treatment of cardiovascular disease (Abernathy and Schwartz, 1999). Although
chemically diverse, these drugs share the common property of inhibiting the action of
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the voltage-gated L-type calcium channels. The ability of these drugs to decrease
smooth muscle and myocardial contractility results in both clinically desirable
antihypertensive and antianginal effects. The established principle of decreasing
bone formation resulting in increasing bone resorption following the attainment of
peak bone mass illustrates the need for a more comprehensive understanding of the
action of these drugs. Experimental evidence suggests that calcium channel
antagonists decrease osteoblastic activity, thus decreasing the activity of the bone
forming cells at a time when bone formation is already exceeded by bone resorption,
thus exacerbating the situation. Clinical medicine is treating one ailment and may
possibly be causing another. The benefits of this type of treatment for cardiovascular
disease may significantly outweigh the adverse effects on the skeletal system.
However, these studies may shed some light on the increase in osteoporosis over the
past twenty years, particularly within the male population instead of simply
attributing it to a longer life span. It is known that there is about a ten-year lag in the
age-related rise in cardiovascular mortality in women compared to men (Lindsay and
Cosman, 2001). This difference is likely attributed to estrogens protective action
prior to menopause and hormonal replacement therapy following menopause. Lastly,
this investigation will hopefully provide insight into which class or classes of calcium
channel antagonists decreases resorptive activity and functions through a mechanism
involving estrogenic effects while at the same time providing maximal cardiovascular
protection, improving the physician's decision during drug selection and highlighting

17

those antagonists which are beneficial to the cardiovascular system but have potential
detrimental effects on the skeletal system.
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METHODS
Animals:

All animal protocols outlined herein were approved by Morehead State University's
Institutional Animal Care and Use Committee (IACUC). Prior to and during the
experimental protocol, all rats were maintained in rooms at 23°C ± 2° on a 12-hour
light/dark photoperiod with free access to tap water and a diet low in phytoestrogens
(Harlen Tekland). The strain of rats used in this study were 24-week old male and
female Brown Norway Rats purchased from Harlan Laboratories through the National
Institute of Aging. This rat was selected as a readily available model widely used by
other investigators as a model for postmenopausal osteoporosis in women. The
number of animals to be employed will reflect that which allows statistical evaluation
of the data from the outlined experimentation. The animals were housed in the
Animal Care Facility in the Department of Biological and Environmental Science.
Food consumption, urinary output, and body weight were continuously assessed
while the animals were housed in metabolic chambers. Veterinary care was provided
by Dr. Philip Prater, DVM.

Blood Pressure Analysis:

Blood pressure was monitored non-invasively in rats via Volume Pressure Recording
(VPR). VPR uses a tail sensor cuff to measure as many as seven different
physiological parameters; systolic blood pressure, diastolic blood pressure, mean tail
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pressure, heart rate, blood volume, blood flow, and tail temperature. Filtering or post
processing software calculations are not required. Blood pressure analysis was
conducted using Kent Scientifics' VPR hardware and software. The VPR acquisition
software is specially designed to automatically measure and display in real-time, all
of the non-invasive blood pressure parameters and waveforms. The animals were
maintained in cages with free access to tap water and a diet low in phytoestrogens
(Harlen Tekland). The animals utilized in the study were 20 wk old Brown Norway
Rats (Figure 1). The animals initially underwent a four week training period allowing
them to acclimate to the blood pressure acquisition procedure. During this time
period each animal was exposed to multiple runs of the blood pressure acquisition
process (twice a week), which included the preheating process and being restrained
and cuffed with the associated hardware. The animals were divided into groups in
order to allow statistical comparison, these treatment groups included; control (male
and female), ovariectomized females, diltiazem (male and female), nifedipine (male
and female), and verapamil (male and female). At the end of the four week training
period (animals now 6 months of age) each animal's blood pressure was taken twice a
week for three weeks to provide a baseline blood pressure. On week four of blood
pressure acquisition, the animal's receiving calcium channel antagonists were
administered a previously determined therapeutic dose (diltiazem 8 mg/kg body
weight, nifedipine 2 mg/kg body weight, and verapamil 8 mg/kg body weight) (Sigma
Aldrich Chemicals) via a daily subcutaneous injection. Blood pressure readings were
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Male and Female Brown Norway Rats
(20 wks of age)

4 wk Training Period
(Stress Reduction)

Control

Diltiazem
(8mg/kg)

Nifedipine
(2mg/kg)

Pre-Heat-30° C

Restrain and Cuff

Volume Pressure Recording (VPR)
Blood Pressure Aquisition

Figure 1. Protocol Outline for Blood Pressure Analysis

21

Verapamil
(8mg/kg)

continued for each animal twice a week for an additional three weeks once they
received their initial treatment dose.

3

H-Tetracycline Protocol for Measurement of Whole Skeleton Bone Resorption:

As illustrated in Figure 2, whole animal measurement of bone resorption was
obtained by labeling the rat skeleton with 3H-tetracycline (PerkinElmer). The male
and female Brown Norway Rats were five months of age upon arrival and were
maintained in metabolic chambers with free access to tap water and a diet low in
phytoestrogens (Harlen Tekland). Each animal underwent a labeling period involving
six subcutaneous injections (one every third day) of 3H-tetracycline dissolved in
0.05M HCl containing ascorbic acid as a reducing agent. Each rat received a total of
36µCi during the labeling procedure and were six months of age at the conclusion of
the labeling process. Following the administration of the final isotope injection,
animals were broken into groups (control, vehicle control, diltiazem, nifedipine, and
verapamil). Animals in each group received a daily, subcutaneous injection of
diltiazem 8 mg/kg body weight, nifedipine 2 mg/kg body weight, and verapamil 8
mg/kg body weight, and urine was collected at 24-hour intervals for a period of 28
days. Urine volume was determined each day and an 0.5 ml aliquot from each
sample was combined with 10 ml of SXl 8-4 Scintiverse BD Cocktail (Fisher
Scientific; Pittsburgh, PA) to determine 3H-tetracycline content by liquid scintillation
spectrometry (Beckman Scintillation Counter). The 3H-tetracycline urinary loss
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Male and Female Brown Norway Rats
(20 wks of age)

Housed in Metabolic Chambers

Labeling Protocol,
Subcutaneous Doses of
3
H-Tetracycline
(36µ.Ci in 6 doses)

Diltiazem
(Smg/kg)

Controls

Nifedipine
(2mg/kg)

Verapamil
(Smg/kg)

Urine Collection
(29 Days)

Competitive Enzyme
Immunoassays

Liquid Scintillation
Spectrometry

Figure 2. Protocol Outline of Metabolic Study
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curve generated for each animal was analyzed by Table Curve 2D Automated Curve
Fitting Software (SPSS INC.; Chicago, IL.) to determine the best fit equation. In
previous experimentation, Wright and DeMoss (2000) have determined that the
individual 3H-tetracycline loss curves were best represented by a double exponential
equation (two-compartment model compromised of two exchangeable bone calcium
pools). The use of this equation to analyze each curve provided the following
parameters for each compartment: (1) the uncomplicated rate of label loss at time
zero with the pool fully labeled; (2) the time constant required for >98% of the pool
to be depleted; (3) the labeled pool size per gram dry skeletal mass; and (4) the total
labeled pool size. In addition, a sample of urine from each day of the experimental
protocol was saved and frozen, for future processing for the presence of various bone
metabolic degradation markers once the holistic experimental process was completed.
Dpd, Pyd, and Helical peptide levels will be corrected for differences in urine
concentration and output by dividing by creatinine (expressed as µg/mmol).

Dry Skeletal Mass Determination:
At the end of the metabolic protocol (Figure 2), skeletal mass was determined and
analyzed as an indicator of imbalance between bone resorption and formation as
indicated by the work ofDeMoss and Wright, 1997 and 1998 and Geng et al, 2000.
Animals were euthanized via CO2 inhalation and body weights were recorded.
Euthanized animals were skinned and disemboweled then dehydrated in a Fischer

24

Isotemp Oven. The dehydrated carcasses were then placed with Dermestid Beetle
colonies (Dermestes maculates, Carolina Biological Supply Co., Burlington, N.C.) to
remove the remaining tissues. Skeletons were then soaked in ethyl alcohol to kill
Dermestid larva and then repeatedly washed in water, lyophilized (LABCONCO
Freeze Dry System) and weighed to obtain dry skeletal weight.

Organ Isotope Extraction:

In order to detect the presence of the bone fluid compartment, 24 week old male and
female Brown Norway Rats underwent an abbreviated (three injections, 72 hours
apart) 3H-tetracycline labeling process 18µCi total (Figure 3). At the conclusion of
the labeling protocol specific bones from both the axial and appendicular skeleton
were removed from the animals at three different sacrifice intervals (48, 96, and 144
hours) following the last isotope injection. Throughout the experimental period the
animals were maintained as previously described under the metabolic study. The
male and female animals were divided into groups of three for both control and
nifedipine. The nifedipine group received a daily dose of 2 mg/kg body weight of
nifedipine (Sigma Aldrich Chemicals) 24 hours after the last isotope injection. The
animals were anesthetized via an LP. injection of sodium pentobarbital followed by
exsanguination via a cardiac puncture. The cardiac puncture was performed in order
to remove any or most of the isotope that may be in circulation. The animals were
then skinned, disemboweled, and the following representative bones were removed
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Male and Female Brown Norway Rats
(24 wks of age)

i
Labeling Protocol, Subcutaneous Doses of
3
H-Tetracycline (18µCi in 3 doses)

t

Control

~

-

~

~

Nifedipine
(2mg/kg)

I\

V

Sacrifice Intervals (48, 96, and 144 hrs
Post Injection Regimen)

i
Removal of Representative Bones of Axial
and Appendicular Skeleton

i
Exposed to dH20

i

~
Liquid
Scintillation
Spectrometry

Lyophilization of Bones

i
Exposed to Weak Acid

-

__/

Figure 3. Protocol Outline for Organ Isotope Extraction
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from the axial and appendicular skeleton: parietal, atlas, 2nd lumbar vertebrae, 2nd
floating rib, ulna, humerus, tibia, and femur. One gram of skeletal muscle was also
removed and utilized as a negative control. The bones were manually cleaned of as
much tissue as possible and exposed to a series of dilutions in distilled water
(leeching process) over a period of nine days. The dilution series consisted of three
different distilled water dilutions, dilution one consisted of the axial bones being
exposed to 5 ml while the skeletal muscle sample and bones of the appendicular
skeleton were placed in 10 ml while dilutions two and three had reduced volumes by
half for all specimens (2.5 ml for the axial and 5 ml for the appendicular and skeletal
muscle tissue). The bones incubated in each dilution for a period of72 hours at 6°C
with daily vortexing. A 0.5ml sample was removed from each dilution and analyzed
for 3H-tetracycline content using liquid scintillation spectrometry. The bones were
then lyophilized, weighed, and dissolved in a dilution series of 0.5M HCL to
determine the amount of 3H-tetracycline label remaining in the calcified portion of
each bone using liquid scintillation spectrometry. The dilution series for the acid was
conducted in the same fashion as that for the distilled water outlined above with the
exception of an additional dilution for the bones of the appendicular skeleton identical
to the third dilution, in order to recover any excess isotope from the calcified
compartment. A 0.5 ml aliquot was removed from each dilution and analyzed for 3Htetracycline content using liquid scintillation spectrometry.
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Statistics:

All data were compared utilizing an ANOVA (Statview for Windows, SAS Institute
Inc.) to determine significant differences. Data was considered significant ifp< 0.05.
All data is expressed as mean± standard error of the mean.
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Results

Blood Pressure Analysis
Blood pressure data was collected from male and female Brown Norway Rats six
months of age over a six week period of time. This analysis involved numerous
experimental groups including animals exposed to the three major classes of calcium
channel antagonists. The data presented in Figures 4-9 illustrate the impact of these
antagonists on diastolic, systolic, and mean tail blood pressure for both sexes.
Comparisons clearly indicate a statistically significant reduction in the diastolic,
systolic, and mean tail blood pressure when compared to controls once specified
groups of animals were injected with one of the three classes of calcium channel
antagonists (P< .0001). The effect of these drugs on the blood pressure parameters
studied for males are found in Figures 4-6 while the female data is expressed in
Figures 7-9. It should be noted that the females receiving these antagonists had
previously undergone surgery to remove their ovaries for a separate study and are
utilized here for comparison purposes only. It is important to point out that the blood
pressure parameters of the control, vehicle control, and ovarectomized groups are not
statistically significant from each other.
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Metabolic Study

An analysis of skeletal turnover was conducted over a 29 day period in which the
effects of calcium channel antagonists were compared between many metabolic
parameters of aged male and female Brown Norway Rats. These parameters included
body mass, dry skeletal mass, % dry skeletal mass, and numerous computer generated
parameters for both the bone fluid and calcified skeletal compartments by monitoring
the loss of 3H-tetracycline. Statistical comparisons were made between sexes and
within each sex for all experimental groups studied. At the conclusion of
3

H-tetracycline collection the animals were sacrificed, weighed, dry skeletal mass

determined, and% dry skeletal mass was calculated (Figures 10-12). The graphical
presentation of body weight in Figure 10 clearly illustrates a statistical difference
between the male and female rats (P< .0001). The statistical comparisons however
did not suggest that the calcium channel antagonists had any adverse effect on the
animals body weight. A similar phenomena is illustrated in Figure 11 as males
clearly possess a significantly larger skeletal mass than females (P< .0001) without
any apparent impact from the calcium channel antagonists. However, when the dry
skeletal mass was normalized for body weight (% dry skeletal mass) a reversal was
observed. Female rats have a significantly larger skeleton per gram of body tissue
than their male counterparts (P< .0001 ). The data however still does not indicate any
influence by calcium channel antagonists on skeletal mass in normal male and female
Brown Norway Rats. It should be noted that the female vehicle control did express
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statistical difference from the control for body weight and % dry skeletal mass
(Figures 10 and 12).
Utilizing Table Curve 2D Software to analyze the loss of 3H-tetracycline in
urine demonstrated that a double exponential regression equation was the best fit
equation for 100% of the experimental animals. This suggests that the turnover of
3

H-tetracycline is from two separate skeletal compartments, which will be referred to

as the bone fluid and calcified skeletal compartments. This software provided
regression data that is representative of the turnover rate for both skeletal
compartments, the time required for these compartments to be depleted, and the
ability to calculate the compartments relative size. These parameters can be further
defined as follows: y-intercept, the uncomplicated rate oflabel loss at time zero with
the bone pool fully labeled, 't, the time constant for depletion of the pool (theoretical
x-intercept), (Cy-intercept ('t x 5))/2), the size of the compartment per gram of tissue,
and the total pool size (pool size/ gram dry skeletal mass)(DSM). Figure 13 presents
the effects of sex and calcium channel antagonists on the depletion rate of the bone
fluid compartment. The statistical analysis indicated that only the male diltiazem and
verapamil groups' differed significantly from their female counterparts (P< .05), but
that a quickly depleted bone fluid compartment was the characteristic trend among
males. No significance was detected within either sex between the controls and the
experimental groups. The turnover rate of the bone fluid compartment (Figure 14)
was greater in males than females. When compared to females the male vehicle
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control, nifedipine, and verapamil treatment groups achieve statistical significance
(P< .05), indicating a faster turnover rate than that found in female Brown Norway
Rats. Comparisons made within sex expressed little significance, only the male
nifedipine group was significant from its corresponding control (P< .05). A general
trend did exist within the females potentially suggesting that calcium channel
antagonists may increase the turnover rate of the bone fluid compartment. The bone
fluid pool size/gm dry skeletal mass (Figure 15) displays sex differences only
between the controls (P< .01). No significance exists between the male and female
groups exposed to calcium channel antagonists clearly suggesting an impact of the
drugs on the female pool size per gram of tissue. This is evident in that significance
was detected in both the diltiazem and verapamil experimental groups when
compared to the vehicle control (P< .05). Diltiazem's pool size was also significantly
larger than the control group (P< .05). When you eliminate the body weight
normalization and consider the total bone fluid pool size males are larger than their
female counterparts (Figure 16). The total bone fluid pool size was significantly
greater in the male controls (P< .05) and those males exposed to nifedipine (P<.05).
Statistical comparisons made within the male groups did not provide significant
differences even though verapamil's total pool size was obviously reduced. Female
comparisons were identical to Figure 15 (pool size per gram of tissue), in that both
diltiazem and verapamil possessed significantly larger pool sizes than the vehicle
control (P< .05) and diltiazem was greater than the normal control (P< .05). It is
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apparent that the calcium channel antagonist's, via some mechanism are influencing
the total pool size in the female treatments when compared to controls.
The pool depletion time for the calcified compartment can be seen in Figure
17 and unlike the bone fluid compartment the time required to empty this
compartment is basically the same between male and female Brown Norway Rats.
The statistical analysis only indicated significance between the male and female
verapamil groups (P< .05). The calcified compartment's resorption rate is
significantly lower in males than females (Figure 18). Four of the five male treatment
groups displayed a significant reduction in their resorption rate (P< .05). The only
exception was the sexual comparison associated with diltiazem but even it followed
the visual trend. No significance was found within male or female treatment groups,
however the females were highlighted by lower resorptive rates for those groups
exposed to calcium channel antagonists. The pool size per gram dry skeletal mass
was significantly lower in three of the five male treatment groups (control, nifedipine,
and verapamil) when compared to their female counterparts (Figure 19). No statistical
significance was detected within either sex following exposure to calcium channel
antagonists. Figure 20 eliminates the body weight normalization and allows
consideration of the total calcified pool size. The total labeled pool size was similar
between the males and females with only one point of significance detected, between
the vehicle control groups (P< .05) and none detected within either sex.
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Organ Isotope Extraction

The amount of isotope collected from the bone fluid compartment in female
Brown Norway Rats is graphically presented with the males allowing sexual
comparisons but also by themselves allowing time interval comparisons due to the
difference in isotope magnitude. The overall loss of 3H-tetracycline from the bone
fluid compartment ofrepresentative bones of both the axial and appendicular skeleton
can be seen as well as the tissue utilized as a negative control in Figures 21-38. The
graphical results indicate a significant decrease (P< .05) in the amount of isotope
present in this pool across the experimental period within each sex and for both the
controls and the animals exposed to nifedipine. This decreasing pattern in 3 Htetracycline concentration varies between each time interval and/or skeletal bone
type. The males possess a significantly larger pool of 3H-tetracycline (P< .05),
undoubtedly due to their larger size. What should be noted is that nifedipine
significantly (p< .05) increased the amount oflabel extracted from bones of the axial
skeletal (Figures 21-28) than that of the appendicular skeleton (Figures 29-36). This
effect is only detected in male comparisons except for the female parietal (Figure 21
and 22) and the 2nd floating rib (Figures 27 and 28). The data for the negative control
differs from that of skeletal tissue (Figure 37 and 38). The magnitude oflabel
extracted from skeletal muscle was significantly less, sexual differences were
detected only at 48hrs and nifedipine had no impact on the pool size. It is noteworthy
that when comparing the isotope extracted from the negative control to the bones of
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the axial skeleton that one gram of skeletal muscle is a lot more tissue than the
specific bone studied.
Once isotope stopped leeching from the bones in distilled H2O each bone was
lyophilized and weighed. Each bone and the control tissue were exposed to a series
of O.SM HCI extractions. The concentrations of isotope released from the calcified
compartment as the inorganic portion of the skeletal tissue was dissolved can be seen
in Figures 39-47. These figures clearly demonstrate that the calcified pool is
significantly (P< .05) larger in males than females except for the atlas and 2nd lumbar
vertebrae (Figures 40 and 41 ). The effects of time and nifedipine on the amount of
isotope remaining in the calcified compartment were not statistically significant. The
negative control (skeletal muscle) expressed no sex, time, or significant differences
due to nifedipine (Figure 47).
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Compartment of the Tibia in Aged Female Brown Norway Rats

1.2E+07

~ P< .05 compared to 96 and 144 hrs
0 P< .05 compared to 144 hrs
µ P< .05 compared to control
• P< .0 I compared to ~

□ Control

18:l Nifedipine

*
B

µ

1.0E+07

8.0E+06

e*

~

ii... 6.0E+06
0,

u

e* e*

-.J

4.0E+06

*

2.0E+06

B

*

e e

0.0E+00

Si! 48 Hrs

Sj2 96 Hrs

Sj2 144 Hrs

cS48Hrs

cJ 96 Hrs

cJ 144 Hrs

Figure 35. Effect of Sex and Nifedipine on the Release of 3H-Tetracycline from the Bone
Fluid Compartment of the Femur in Aged Brown Norway Rats

fl P< .05 compared to 96 and 144 hrs
e P< .05 compared to 144 hrs
µ P< .05 compared to control

1.0E+06
□ Control

f3

9.0E+0S

l2l Nifedipine

8.0E+0S
7.0E+0S
6.0E+0S
~
CJ>

0,

~

u

f3

e

5.0E+0S

e

4.0E+0S
3.0E+0S
2.0E+0S
1.0E+0S
0.0E+00
~ 48 Hrs

~ 96 Hrs
3

~ 144 Hrs

Figure 36. Effect ofNifedipine on the Release of H-Tetracycline from the Bone Fluid
Compartment of the Femur in Aged Female Brown Norway Rats

p

6.0E+04

P< .05 compared to 96 and 144 hrs
0 P< .05 compared to 144 hrs
* P< .05 compared to 'i'
□ Control

121 Nifedipine

*
13

5.0E+04

13
4.0E+04

CJ)

CD

If
u

3.0E+04

13
0

2.0E+04

1.0E+04

<j? 48 Hrs

<j? 96 Hrs

<j? 144 Hrs

<3 48Hrs

<3 96 Hrs
3

<3 144 Hrs

Figure 37. Effect of Sex and Nifedipine on the Release of H-Tetracycline from
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Figure 47. Effect of Sex and Nifedipine on H-Tetracycline Concentration in the
Skeletal Muscle in Aged Brown Norway Rats

Discussion
Blood Pressure Analysis
Blood pressure was monitored in both male and female Brown Norway Rats six
months of age following their exposure to calcium channel antagonists (diltiazem,
nifedipine, or verapamil), compounds routinely prescribed for the treatment of high
blood pressure in humans. This analysis clearly illustrates the impact of these drugs
on male and female blood pressure when continuously given over a three week period
which indicates that as the plasma level of calcium channel antagonists are increased
and maintained, blood pressure is reduced accordingly. This observation has been
routinely demonstrated in rodent models (Imai et al., 1994). The results indicate an
immediate significant decrease in systolic, diastolic, and mean tail blood pressure for
all groups receiving an antagonist (Figures 4-9) just as Waeber et al. (1985) has
demonstrated for verapamil. The female data (DeMoss, unpublished) was extracted
from a previous study focusing on a reduction in circulating levels of estrogen in rats
that had been ovariectomized. The female experimental groups illustrate the same
statistical findings as their male counterparts. Since the female control and
ovariectomized groups were not significant from each other, these groups were
utilized for comparison purposes instead ofrepeating the study with nonovariectomized animals. The vehicle control also provides evidence that the solvent
used to dissolve the drugs is not responsible for the significant drop in blood pressure
characteristic when the animals were exposed to calcium channel antagonists.
Together the male and female data suggest that the concentrations of calcium channel
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antagonists utilized during the experimental period for both sexes of Brown Norway
Rats were sufficient to induce a significant reduction in cardiovascular activity.

Metabolic Study
Analysis of skeletal turnover from this research allowed a comparison of the
effects of calcium channel antagonists on aged male and female Brown Norway Rats
to be made through the utilization of the in-vivo 3H-tetracycline Rat Model. This
methodology allows monitoring of 3H-tetracycline release from the skeleton of
exposed animals in order to demonstrate bone matrix resorption through renal
activity. This physiologically relevant marker is considered to be a direct indicator of
bone resorption and has been routinely used for whole animal studies (Klein, 1983).
Utilization of this model allowed an examination of the following metabolic
parameters: rate of bone resorption, pool depletion time, 3H-tetracycline pool size per
gram of dry skeletal mass, and the total 3 H-tetracycline pool size. When the metabolic
experiment was terminated on day 29, body weight and dry skeletal mass were also
obtained and % dry skeletal mass calculated.
Though the data for body weight (Figure 10), dry skeletal mass (Figure 11 ), and

% dry skeletal mass (Figure 12) clearly express a sex difference, they also indicate
that calcium channel antagonists do not influence these easily obtainable parameters.
The sex differences were expected and demonstrate hallmark characteristic
differences between male and female rats (DeMoss, 1998). Not expected were the
statistical differences observed between the female control and vehicle control groups
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for body weight and% dry mass. These differences were most likely due to the
arrival time of animals from Harlan since the animals placed in the vehicle control
group were obviously smaller when they were received and as a result were
significantly smaller at the onset of experimentation.
As expected the greater overall size of the male animals (Figure 10) resulted in
larger skeletons than their female counterparts (Figure 11 ). Larger animals require a
larger skeleton to support their greater mass. However, when the data was
normalized for body weight the females displayed a significantly larger skeleton per
gram of body tissue than their male counterparts (Figure 12). This greater percentage
has been routinely attributed to greater demands placed on the female skeleton during
the bearing and rearing of young, factors males are not faced with (DeMoss, 1998).
This would suggest that the size of the rat skeleton is not entirely correlated with
body weight (Wright et al., 2000).
The metabolic parameters of skeletal activity for the bone fluid compartment in
male Brown Norway Rats exposed to calcium channel antagonists suggest no
apparent physiological effect. No statistical significance was found in the time
required for the pool to be depleted (Figure 13). Limited significance was detected
within male treatment groups for the turnover rate of the bone fluid compartment
(Figure 14). Only the group of animals exposed to nifedipine showed any apparent
stimulation in metabolic activity. Since the x and y-intercepts were not significantly
affected by the drugs in aged male Brown Norway Rats, it only makes sense that the
metabolically active pool size per gram of dry skeletal mass (Figure 15) and the total
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metabolically active pool (Figure 16) would show no significant changes between
treatment groups. These findings suggest that calcium channel antagonists had no
apparent effect on the physiological activity of the male bone fluid compartment.
However, the metabolic parameters of skeletal activity for the bone fluid
compartment in female Brown Norway Rats exposed to calcium channel antagonists
suggests an increase in the turnover of this compartment consistent with previous
work published by DeMoss and Wright 1997, 2000. No statistical significance was
found in the time required for the pool to be depleted, (Figure 13). There was
however considerable variability within the data. The turnover rate of the bone fluid
compartment did not present any statistical significance but did demonstrate a
potential drug induced effect when compared to the controls (Figure 14). One would
assume that ifx and y-intercepts were not altered, then no apparent effects should be
seen in either the metabolically active pool size per gram of dry skeletal mass (Figure
15) or the total metabolically active bone fluid pool (Figure 16). This is not the case
because the females exposed to the calcium channel antagonists all demonstrated an
increase in the metabolically active pool size per gram dry skeletal mass and total
metabolically active bone fluid pool. This can only be accounted for by the
nonsignificant trend (increase) observed in the turnover rate of Figure 14. The groups
of female animals exposed to the calcium channel antagonists diltiazem and
verapamil demonstrated a significant increase in pool size per gram dry skeletal mass
during the experimental period due to the apparent increase in the turnover rate of the
bone fluid compartment.

83

With regards to sexual differences, male Brown Norway Rats appear to have a
greater turnover rate (Figure 14) and thus the time required for them to deplete the
bone fluid compartment (Figure 13) is quicker than that of female Brown Norway
Rats. The overall size of the bone fluid compartment in males is significantly greater
than that of females (Figure 16). This makes sense because males are larger animals
than females and you would expect them to have a larger bone fluid compartment.
The only potential exception to this conclusion is the impact of verapamil on the male
bone fluid compartment. The significance of verapamil decreasing the male xintercept and its resulting influence on pool size per gram of dry skeletal mass as well
as total pool size will require further investigation.

If the drug dosage was increased in males, would results similar to that of females
occur in the bone fluid compartment? It is evident, however, that the dosage utilized
in this study was great enough to impact the cardiovascular system, in both males and
females, significantly lowering blood pressure.
The metabolic parameters of skeletal activity for the calcified compartment in
male and female Brown Norway Rats exposed to calcium channel antagonists suggest
no apparent physiological effect. No statistical significance was found between
treatment groups for the time required to deplete the pool (Figure 17) or the bone
resorption rate (Figure 18). Since the x and y-intercepts were not significantly altered
by the drugs in aged male and female Brown Norway Rats it only makes sense that
the metabolically active pool size per gram dry skeletal mass (Figure 19) and the total
metabolically active calcified pool (Figure 20) possessed no significant differences
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between treatment groups. These findings would indicate that calcium channel
antagonists had no apparent effect on the physiologic activity of the male and female
calcified bone compartment. It is probably worth mentioning that the female
treatment groups exposed to calcium channel antagonists had a lower bone resorption
rate. This decrease was not significant and did not impart any impact on the pool size
per gram dry skeletal mass or total pool size. This appears important because data
previously collected in female animals that have undergone ovariectomy or had
hypertension were significantly effected (DeMoss, unpublished and Wight and
DeMoss 2000).
With regard to sexual differences, female Brown Norway Rats have a
significantly greater bone resorption rate than their male counterparts (Figure 18).
The time required to empty the pool appears to be the same between males and
females (Figure 17) but the metabolically active calcified pool size per gram dry
skeletal mass is significantly greater in females (Figure 19). Their basal level of
resorption is greater than males and as a result the normalized pool per gram is larger
than their male counterparts. When the body weight normalization is removed,
(Figure 20) the total metabolically active calcified pool is not significant between
males and females. This probably reflects the fact that the animals were injected with
a common amount of isotope but more importantly that the rate of bone formation in
males and females is apparently similar in aged Brown Norway Rats in order for the
total calcified pool size not to be statistically significant.
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The data suggests that the calcium channel antagonists employed in this study are
not having quite the effects on the calcified compartment of males and females as
they are on the bone fluid compartment of the normal females. The treatment of the
candidate calcium channel antagonists (diltiazem, nifedipine, and verapamil) does not
demonstrate a clear significant impact on the skeletal physiology, of the tested
metabolic parameters, in either male or female aged Brown Norway rats. The
clearest difference in any of the studied parameters appears to be of a sexual nature,
indicating that sex most definitely has an impact on the skeletons physiological
mechanisms. However the fact that the calcium channel antagonists increase the
turnover rate of the bone fluid compartment and that this results in significant
changes in the pool size per gram and total bone fluid pool size is obviously very
significant. The fact that these same drugs lower the resorption rate of the calcified
compartment but did not significantly influence pool size is of particular interest in
the lab. It has already been demonstrated that females that have been ovariectomized
and treated with calcium channel blockers have lowered resorption rates than those
females that were ovariectomized but not treated with calcium channel antagonists
(DeMoss, unpublished).

Organ Isotope Extraction

In an attempt to study the bone fluid and calcified compartments and support the
conclusions drawn from the metabolic procedures with regard to the existence of both
a labile (bone fluid compartment) and stable (calcified compartment) pool of calcium
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organ isotope extraction was utilized. The design of the study allowed me to make
sexual comparisons and study the impact of one of the classes of calcium channel
antagonists (1,4-dihydropyridines,(nifedipine)) on these pools.
As would have been expected, the bone fluid and calcified pool size was
statistically greater in males than in females. Based on physical size of the animals
utilized, one would naturally expect that exposing these animals to an isotope with an
affinity for skeletal tissue, that more isotope would be taken up by the skeletal
compartments of the larger males. The data also clearly suggests that isotope not
deposited into the calcified matrix can be leeched out and significantly decreases over
time intervals studied for both males and females. Since the amount of isotope is
decreasing does that suggest that isotope enters into the bone fluid compartment and
then enters the caicified matrix or does it enter and then just wash out with time?
Since a significant concentration of isotope is detected in the calcified matrix that
couldn't be extracted with distilled water, it is concluded that the isotope enters into
this labile pool and associates itself with elements that could be deposited in active
mineralization during the labeling period. Thus, it is possible that some of the isotope
may never have been deposited into the matrix and as a result is in a readily
exchangeable pool of elements that can be removed from the bone fluid compartment
and excreted in the urine. The data does not suggest that the size of the calcified
compartment is increasing as isotope moves from the bone fluid compartment into the
calcified compartment after the injections have stopped. This could be due to the fact
that as some of the isotope moves into active sites for deposition that some isotope is
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being resorbed from other sites and excreted. This would support data obtained from
the calcified compartment in that basically no statistical significance exists between
the time intervals of sacrifice. There appears to be no distinguishable physiological
trend in bones selected from either the axial or appendicular skeleton. It would
appear that the calcified compartment for these individual bones whether they are
weight-bearing or nonweight-bearing only display what is routinely described as
individuality as suggested by Wright et al. and Geng et al. in 2000.
The calcium channel antagonist, nifedipine, utilized in the study appears to
influence the physiological activity of the skeleton. This compound exerts no
apparent impact on the amount of isotope present in the calcified compartment while
significantly altering the uptake or release of the isotope from the bone fluid
compartment. The impact is best seen in the bones of the axial skeleton (Figures 2128) and is more extensively seen in males than females. Thus, it would appear that
injecting animals with nifedipine following the labeling period is affecting isotope
release or some how stimulating increased uptake. Isotope release does significantly
decrease over time while the animal is receiving nifedipine, since the amount present
in the calcified compartment is not significantly increased, this would either suggest
increased calcified remodeling or increased transport of the isotope into the bone fluid
compartment at the onset of the nifedipine exposure while significant levels of the
isotope are still circulating.

It would appear that each bone has its own physiological parameters or
individuality making each of these organs slightly different from other members of
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the skeletal network. The data also would suggest that bones of the axial skeleton
which possess a greater percentage of trabecular bone per gram of skeletal mass have
their ability to exchange isotope altered following exposure to the calcium channel
antagonist, nifedipine. The fact that bones of the axial skeleton were the most
influenced was not unexpected since Geng et al. 2000 had already indicated that the
metabolic rate of bones from the axial skeleton had a faster turnover rate than bones
from the appendicular skeleton. Further experimentation that includes other calcium
channels may yield more conclusive evidence about the effects that these drugs have
on the bones physiology.
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